We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A nearly two-year antitrust investigation by the Justice Department that involves more than a dozen generics makers could result in price-collusion charges before the year ends, according to a source familiar with the matter. Read More
The UK Court of Appeal affirmed an earlier ruling that invalidated Pfizer’s patent claims for Lyrica and ruled generics would not lead to infringements. Read More
Drugmakers have expressed concern about the German government’s proposal to restrict drug pricing — contending that the measure penalizes research and development. Read More
The antitrust division of the Justice Department has issued subpoenas to a Mylan executive and certain employees over the pricing of four generic drugs. Read More
A federal appellate court is remanding a False Claims Act suit that alleges Fresenius overcharged Medicare for dialysis treatments — ruling that the whistleblower lacked standing based on a reliance on secondhand accounts. Read More
A federal judge awarded the Federal Trade Commission its request to dismiss a pay-for-delay suit that alleges Endo Pharmaceuticals blocked the market entry of Opana ER and Lidoderm generics. Read More
Sen. Chuck Grassley (R-Iowa) is continuing his investigation into Mylan’s ballooning pricing of the EpiPen and government rebates that it has received, requesting more information in the latest of a series of letters to manufacturer and several federal agencies. Read More
A group of bipartisan lawmakers have called on Mylan to repay the Department of Defense (DoD) for overcharging the military at retail pharmacies for its emergency allergy treatment, the EpiPen. Read More
The U.S. Supreme Court has paved the way for non-cash patent settlements to trigger antitrust scrutiny after it refused to hear a case involving GlaxoSmithKline’s epilepsy therapy Lamictal. Read More